MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Multiple system atrophy(MSA): Treatment"

  • 2024 International Congress

    Incorporating the Voice of the Patient and Caregiver into a Multiple System Atrophy (MSA) clinical trial

    J. Marer, G. Krog, D. Houghton, J. Nettleship, M. Chen, L. Marinelli (Netanya, Israel)

    Objective: To understand patient and caregiver preferences and perceptions of a proposed clinical trial design for an interventional drug targeting Multiple System Atrophy. Background: Stakeholders…
  • 2024 International Congress

    A Phase 1b Randomized, Placebo-Controlled, Delayed-Start Trial of UB-312 in Synucleinopathies.

    P. Millar Vernetti, D. Mirski, JC. Dodart, A. Wood, HJ. Yu, J. Boyd, P. Kundu, R. Setton, D. Silbersweig, E. Stern, C. Lucero, S. Gerrol, H. Kaufmann, J. Martinez (New York, USA)

    Objective: Assess safety and immunogenicity of UB-312 in a phase 1b trial in Multiple System atrophy (MSA) or Parkinson’s disease (PD). Background: Abnormal deposition of…
  • 2024 International Congress

    SNCA Antisense Oligonucleotide for Multiple System Atrophy: HORIZON Trial Update

    K. Meilleur, K. Seppi, F. Krismer, R. Simoes, T. Lampreia, J. Corvol, S. Sambin, G. Hoglinger, C. Schindler, A. Schnitzler, C. Hartmann, K. Eggert, H. Pape, A. Ludolph, J. Kassubek, O. Rascol, M. Rumbel, D. Schulz, S. Darrow, Y. Deng, P. Gupta, S. Stanton, J. Esteban, H. Zhao, M. Yarborough, R. Fong (Carlsbad, USA)

    Objective: To provide an update on the baseline demographics and safety from the HORIZON Clinical Trial of ION464 Background: Multiple System Atrophy (MSA) is a…
  • 2024 International Congress

    Long-term Safety of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

    R. Freeman, I. Biaggioni, R. Vickery, L. Norcliffe-Kaufmann, T. Guerin, M. Bryarly, V. Iodice, M. Rudzniska-Bar, M. Boczarska-Jedynak, C. Oehlwein, C. Shibao, H. Kaufmann (Boston, USA)

    Objective: To assess the long-term safety and tolerability of ampreloxetine in patients with synucleinopathies (MSA, PD, and PAF) and symptomatic neurogenic orthostatic hypotension (nOH) from…
  • 2024 International Congress

    Autoradiography characterization of novel alpha-synuclein radioligands [3H]Tg1-90B, [3H]M503-1619 and [3H]HY-2-15 in human post mortem brain

    D. Saturnino Guarino, G. Tian, K. Ho Young, H. Cj, V. Lee, K. Luk, R. Mach (Philadelphia, USA)

    Objective: To characterize the in vitro binding properties of 3 radioligands for imaging α-syn aggregates in post mortem brain samples of synucleinopathies: [3H]TG-190B (Site 2),…
  • 2024 International Congress

    Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial

    A. Amoushahi, A. Sahebkar, P. Moeini, N. Chitsaz (Isfahan, Islamic Republic of Iran)

    Objective: Iron removal seems to be a treatment approach in Multiple system atrophy (MSA) because pathological findings shows the accumulation of iron and α-synuclein protein…
  • 2024 International Congress

    A Phase 2 Study of ATH434 a Novel Inhibitor of α-Synuclein Aggregation for the Treatment of Multiple System Atrophy

    D. Stamler, C. Wong, P. Trujillo, M. Bradbury, C. Lucas, D. Claassen (Newark, USA)

    Objective: Describe baseline fluid and neuroimaging biomarker data of an early MSA study population Background: MSA is a rapidly progressive neurodegenerative disorder characterized by aggregated…
  • 2024 International Congress

    Multifaceted Challenges in Multisystem Atrophy Management: Medication Sensitivity, Emotional Lability, and Increased Fall Risk

    G. Legerme, B. Carr, C. Rowan (Gainesville, USA)

    Objective: Multisystem atrophy (MSA) epitomizes a formidable quandary within neurological and geriatric disciplines, delineated by complex manifestations encompassing autonomic dysfunction, parkinsonism, and cerebellar ataxia. This…
  • 2024 International Congress

    Pharmacokinetics And Safety Of YA-101, A Dual Inhibitors Of D-Amino Acid Oxidase (DAAO) And NLRP3 Inflammasome, In Healthy Subjects: A Double-Blind, Placebo-Controlled, Randomized, Single Dose and Multiple Dose Phase I Study

    YJ. Tseng, BH. Su, O. Lin, DZ. Luo, TF. Lo, YC. Huang, CC. Li (Taipei, Taiwan)

    Objective: To evaluate the safety, tolerability, and pharmacokinetics (PK) profile of YA-101 in healthy volunteers with single dose and multiple dose Background: Multiple System Atrophy…
  • 2024 International Congress

    Effect of rehabilitation therapy on the motor functions in patients with multiple system atrophy

    J. Lee, S. Jo, M. Choi, SJ. Chung (Seoul, Republic of Korea)

    Objective: We aim to evaluated the effect of rehabilitation therapy on the motor symptoms and activities of daily living in patients with MSA using an…
  • 1
  • 2
  • 3
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley